Rentschler Biopharma Takes First Steps in US Expansion Project
Rentshler Biopharma has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
Rentshler Biopharma, a contract development and manufacturing organization (CDMO) headquartered in Germany, has begun its expansion project in the United States by putting a single-use bioreactor into operation at the Milford facility in Massachusetts.
In a Nov. 6, 2019 press release, the company announced that the XDR-500 bioreactor, which has a working volume of 100–500 L and downstream capabilities of 2–8 g/L, will be part of the good manufacturing practice (GMP) facility suite concept. The company anticipates that the system will be ready for clients by mid-2020, and it is currently being prepared for technology transfer.
Additionally, Rentshler Biopharma revealed some other expansion plans, including another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing and will feature lab capacity for new modalities. Through its client-centric approach, the company aims to facilitate robust and scalable production of complex biomolecules in both Europe and the US.
Source: Rentschler Biopharma
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
